Olanzapine versus placebo in adolescents with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled trial

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 48, Issue 1, 2009, Pages 60-70

  Kryzhanovskaya, Ludmila ^a   Schulz, S Charles ^b   McDougle, Christopher ^c   Frazier, Jean ^d   Dittmann, Ralf ^a   Robertson Plouch, Carol ^a   Bauer, Theresa ^a   Xu, Wen ^a   Wang, Wei ^a   Carlson, Janice ^a   Tohen, Mauricio ^a   Kryzhanovskaya, Ludmila A ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c INDIANA UNIVERSITY   (United States)

^d MCLEAN HOSPITAL   (United States)

Author keywords

Efficacy; Olanzapine; Schizophrenia; Tolerability

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HALOPERIDOL; LEVOMEPROMAZINE; LIVER ENZYME; NEUROLEPTIC AGENT; OLANZAPINE; PIRACETAM; PLACEBO; PROLACTIN; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; TRIFLUOPERAZINE; URIC ACID; ZIPRASIDONE;

ADOLESCENT; ARTICLE; BEDTIME DOSAGE; BODY WEIGHT; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERPROLACTINEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; INCREASED APPETITE; LIMB PAIN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; VOMITING; WEIGHT GAIN;

EID: 58249139362     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1097/CHI.0b013e3181900404     Document Type: Article

References (43)

1. Dass S, McNamara NK, Findling RL. Pharmacological treatment. In: Findling RL, Schulz SC, eds. Juvenile-Onset Schizophrenia: Assessment, Neurobiology, and Treatment. Baltimore: The Johns Hopkins University Press; 2005:17-42.
2. Schulz SC, Findling RL, Wise A, Friedman L, Kenny J. Child and adolescent schizophrenia. Psychiatr Clin North Am. 1998;21:43-56.
3. Kumra S, Frazier JA, Jacobsen LK et al. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry. 1996;53:1090-1097.
4. Realmuto GM, Erickson WD, Yellin AM, Hopwood JH, Greenberg LM. Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. Am J Psychiatry. 1984;141:440-442.
5. Frazier JA, McClellan J, Findling RL et al. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics. J Am Acad Child Adolesc Psychiatry. 2007;46:979-988.
6. Werry JS, McClellan JM, Andrews LK, Ham M. Clinical features and outcome of child and adolescent schizophrenia. Schizophr Bull. 1994;20:619-630.
7. Martin A, Leslie D. Trends in psychotropic medication costs for children and adolescents, 1997-2000. Arch Pediatr Adolesc Med. 2003;157:997-1004.
8. Kumra S, Oberstar JV, Sikich L et al. Efficacy and tolerabilicy of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull. 2008;34:60-71.
9. Spencer EK, Kafantaris V, Padron-Gayol MV, Rosenberg CR, Campbell M. Haloperidol in schizophrenic children: early findings from a study in progress. Psychopharmacol Bull. 1992;28:183-186.
10. Pool D, Bloom W, Mielke DH, Roniger JJ Jr, Gallant DM. A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Curr Ther Res Clin Exp. 1976;19:99-104.
11. Krishnamoorthy J, King BH. Open-label olanzapine treatment in five preadolescent children. J Child Adolesc Psychopharmacol. 1998;8:107-113.
12. Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl). 1996;124:159-167.
13. Tollefson GD, Beasley CM Jr, Tran PV et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457-465.
14. Correll CU, Carlson HE. Endocrine and metabolic advetse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2006;45:771-791.
15. Kaufman J, Birmaher B, Brent D et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36:980-988.
16. Overall JE, Pfefferbaum B. The Brief Psychiatric Rating Scale for Children. Psychopharmacol Bull. 1982;18:10-16.
17. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised (DHEW Publ No ADM 76-538). Rockville: U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
18. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
19. Yudofsky SC, Silver JM, Jackson W, Endicott J, Williams D. The Ovett Aggression Scale for the objective rating of verbal and physical aggression. Am J Psychiatry. 1986;143:35-39.
20. Burtis CA, Ashwood ER, eds. Teitz Textbook of Clinical Chemistry. 3rd ed. Philadelphia: WB Saunders; 1999.
21. NCEP. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Tteatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Treatment Panel III. JAMA. 2001;285:2486-2497.
22. American Diabetes Association/American College of Cardiology. Diabetes and Cardiovascular Disease Review: Diabetic Dyslipidemia. Rep. 3. 2002.
23. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
24. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
25. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia [letter]. Arch Gen Psychiatry. 1982;39:486-487.
26. Mozes T, Greenberg Y, Spivak B, Tyano S, Weizman A, Mester R. Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: an open-label study. J Child Adolesc Psychopharmacol. 2003;13:311-317.
27. Dittmann RW, Meyer E, Freisleder FJ et al. Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study. J Child Adolesc Psychopharmacol. 2008;18:54-69.
28. Ross RG, Novins D, Parley GK, Adler LE. A 1-year open-label trial of olanzapine in school-age children with schizophrenia. J Child Adolesc Psychopharmacol. 2003;13:301-309.
29. Ercan ES, Kutlu A, Varan A, Cikoglu S, Coskunol H, Bayraktar E. Olanzapine treatment of eight adolescent patients with psychosis. Hum Psychopharmacol. 2004;19:53-56.
30. Soderstrom H, Rastam M, Gillberg C. A clinical case series of six extremely aggressive youths treated with olanzapine. Eur Child Adolesc Psychiatry. 2002;11:138-141.
31. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology. 2004;29:133-145.
32. Ratzoni G, Gothelf D, Brand-Gothelf A et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry. 2002;41:337-343.
33. Patel NC, Crismon ML, Hoagwood K, Jensen PS. Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents. J Child Adolesc Psychopharmacol. 2005;15:270-284.
34. Saari K, Lindeman S, Koponen H, Jokelainen J, Isohanni M. Higher seram triglyceride levels in early-onset schizophrenia. Am J Psychiatry. 2004;161:176.
35. Lamon-Fava S, Wilson PW, Schaefer EJ. Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 1996;16:1509-1515.
36. Alfaro CL, Wudarsky M, Nicolson R et al. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol. 2002;12:83-91.
37. David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther. 2000;22:1085-1096.
38. Saito E, Correll CU, Gallelli K et al. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Chim Adolesc Psychopharmacol. 2004;14:350-358.
39. Frazier JA, Alaghband-Rad J, Jacobsen L et al. Pubertal development and onset of psychosis in childhood onset schizophrenia. Psychiatry Res. 1997;70:1-7.
40. Pappagallo M, Silva R. The effect of atypical antipsychotic agents on prolactin levels in children and adolescents. J Child Adolesc Psychopharmacol. 2004;14:359-371.
41. Gonzalez-Heydrich J, Raches D, Wilens TE, Leichtner A, Mezzacappa E. Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination. J Am Acad Child Adolesc Psychiatry. 2003;42:1227-1233.
42. Tran PV, Hamilton SH, Kuntz AJ et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997;17:407-418.
43. McConville BJ, Sorter MT. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry. 2004;65(Suppl 6):20-29.